Retinoic acid agonists inhibited tumor growth in vivo in ACC patient‐derived xenograft models and decreased MYB binding at translocated enhancers, thereby potentially diminishing the MYB positive feedback loop driving ACC [48]. The gene discussed is MYB; the disease is neoplasm.